Genetic determinants of glucose-6-phosphate dehydrogenase activity in Kenya by Shah, SS et al.
Shah et al. BMCMedical Genetics 2014, 15:93
http://www.biomedcentral.com/1471-2350/15/93
RESEARCH ARTICLE Open Access
Genetic determinants of glucose-6-phosphate
dehydrogenase activity in Kenya
Shivang S Shah1,5*, Alex Macharia2, Johnstone Makale2, Sophie Uyoga2, Katja Kivinen3, Rachel Craik1,
Christina Hubbart1, Thomas E Wellems5, Kirk A Rockett1, Dominic P Kwiatkowski1,3 and
Thomas N Williams2,4
Abstract
Background: The relationship between glucose-6-phosphate dehydrogenase (G6PD) deficiency and clinical
phenomena such as primaquine-sensitivity and protection from severe malaria remains poorly defined, with past
association studies yielding inconsistent and conflicting results. One possibility is that examination of a single genetic
variant might underestimate the presence of true effects in the presence of unrecognized functional allelic diversity.
Methods: We systematically examined this possibility in Kenya, conducting a fine-mapping association study of
erythrocyte G6PD activity in 1828 Kenyan children across 30 polymorphisms at or around the G6PD locus.
Results: We demonstrate a strong functional role for c.202G>A (rs1050828), which accounts for the majority of
variance in enzyme activity observed (P = 1.5 × 10−200, additive model). Additionally, we identify other common
variants that exert smaller, intercorrelated effects independent of c.202G>A, and haplotype analyses suggest that each
variant tags one of two haplotype motifs that are opposite in sequence identity and effect direction. We posit that
these effects are of biological and possible clinical significance, specifically noting that c.376A>G (rs1050829)
augments 202AG heterozygote risk for deficiency trait by two-fold (OR = 2.11 [1.12 - 3.84], P = 0.014).
Conclusions: Our results suggest that c.202G>A is responsible for the majority of the observed prevalence of G6PD
deficiency trait in Kenya, but also identify a novel role for c.376A>G as a genetic modifier which marks a common
haplotype that augments the risk conferred to 202AG heterozygotes, suggesting that variation at both loci merits
consideration in genetic association studies probing G6PD deficiency-associated clinical phenotypes.
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Background
Glucose-6-phosphate dehydrogenase (G6PD) is a house-
keeping enzyme encoded on chromosome X. It is ubiq-
uitously expressed in all body tissues and found in
eukaryotes and prokaryotes alike. G6PD catalyses the
rate-limiting first step in the pentose phosphate pathway,
generating NADPH, an electron donor important in a
variety of metabolic processes, including fatty and nucleic
acid synthesis, nitric oxide production, and the regen-
eration of antioxidant glutathione. Deficiency of G6PD
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is the most common enzymopathy in man, with preva-
lence especially high in sub-Saharan Africa and southeast
Asia. It is a trait that is thought to be both harmful and
beneficial. While clinical penetrance is generally mild,
G6PD deficiency can predispose to hemolytic anemia
and neonatal jaundice, generally in the context of oxi-
dant stressors generated by certain foods, medications,
and infections. Counterbalancing these deleterious effects
is evidence that suggests G6PD deficiency confers partial
protection against malaria, and that such protection has
conferred a selective advantage to G6PD-deficient indi-
viduals in malaria-endemic regions, as reflected in the
close geographical correlation between the global distri-
bution of G6PD deficiency and that of historical malaria
endemicity.
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Despite decades of research, however, our understand-
ing of both beneficial and deleterious clinical phenotypes
associated with G6PD deficiency remains incomplete.
Association studies of severe malaria have disagreed over
the strength and specificity of protection, especially with
respect to gender, with past studies demonstrating protec-
tion for only males [1], only females [2], both [3,4], or nei-
ther [5]. Additionally, there is geographical heterogeneity
in association testing results as well, with the only com-
pelling evidence thus far coming from west Africa. Simi-
larly, the precise determinants of the hemolytic response
to oxidative stressors remain unknown. One especially
important drug reaction is that involving the antimalarial
primaquine [6,7]. It is currently the only medication capa-
ble of radical cure of Plasmodium vivax infection and one
of few drugs that acts against the Plasmodium falciparum
gametocyte; it therefore has high value in eliminating
reservoirs of infection and reducing transmission rates,
tasks that are crucial to the success of any malaria elim-
ination program [8]. While G6PD deficiency alleles are
strongly associated with increased risk to primaquine-
induced hemolysis, there exists significant unexplained
variance in this association, especially for mosaic female
heterozygotes [9].
One challenging aspect to designing and interpreting
clinical association studies lies in how G6PD deficiency
is defined. While many genetic association studies at
G6PD implicitly assume that one nonsynonymous cod-
ing variant has both full positive and negative predictive
power for G6PD deficiency trait, this approach belies
the considerable allelic heterogeneity present at the locus
[4,10,11]. Indeed, G6PD deficiency is perhaps best under-
stood as a family of heritable traits exhibiting widely
varying prevalence, as well as differential biochemical
and clinical penetrance, all factors which influence the
power of an association test [4]. Additionally, it is possi-
ble that unrecognized genetic modifiers of G6PD activ-
ity have yet to be identified, and that these may play
a role in determining an individual’s G6PD deficiency
status.
To inform our understanding of how genetic variation at
G6PD impacts clinical outcomes, we sought to examine its
more immediate relationship with molecular phenotypes.
We took a comprehensive two-part approach, first rese-
quencing the G6PD gene to validate known and discover
novel variants, and then testing those polymorphisms for
association with G6PD enzyme activity in Kenya.
Methods
Ethics statement
Ethics approval was granted by the Kenya Medical
Research Institute (KEMRI) review board, and written
informed consent was obtained from a parent or guardian
prior to enrollment.
Sample collection
Capillary blood was drawn by heel prick from 2100
healthy infants (less than 6 months old) of predominantly
Mijikenda ethnicity, recruited into an ongoing prospective
birth cohort study run by KEMRI and theWellcome Trust
in Kilifi, Kenya (SCC1192: The genomic epidemiology of
childhood diseases in Kilifi, Kenya). Samples were stored
in EDTA at 4°C and processed for activity assays and DNA
extraction within four days. Of note, serial assay measure-
ments taken on the same samples remained consistent
even up to 10–14 days from collection.
Enzyme activity assay
The assay used is a ten-fold scaled down version of the
‘macro’ assay given in Randox Laboratories G6PD kit
(PD 410), using positive (PD 2618) and negative (PD
2617) controls where necessary. Ten microliters of whole
blood was washed three times in 100 μl normal saline.
Washed RBC were lysed by incubation with 25 μl of
digitonin for 15 minutes at 4°C. Five microliters of the
hemolysate was incubated with 300 μl of buffer (31.7 mM
triethanolamine, 3.2 mM EDTA, pH = 7.6) and 10 μl
NADP+ (0.34 mM) at 37°C for 5 minutes. Finally, five
microliters of glucose-6-phosphate (0.58 mM) was added
and spectrophotometry readings taken, with duplicate
measurements taken for each sample. Catalytic rate was
assessed by the formation of reaction product NADPH,
which absorbs light at 340 nm. The change in absorbance
at 340 nmwasmeasured over a 3minute time course using
a plate spectrophotometer (Tecan). As we were unable to
obtain hemoglobin or RBC concentrations for our sam-
ples to allow for reporting of activity in international
units, activity is instead reported here in arbitrary units
and was normalized to hemolysate hemoglobin content by
recording absorbance at 540 nm:
G6PD activity =
OD340
t
OD540
Sequencing and genotyping
Resequencing was performed as part of an exon sequenc-
ing project called ExoSeq at Wellcome Trust Sanger Insti-
tute (WTSI). A total of 288 individuals comprised our
sample set, with 48 individuals each from Burkina Faso,
Cameroon, Nigeria, Kenya, Vietnam, and Papua New
Guinea. A total of 28 amplicons approximately 600–800
bp in lengthwere designed via automated algorithm (i.e. in
silico PCR), covering about two-thirds of the 15 kb G6PD
gene, with full coverage of all exons, but a few gaps in
noncoding sequence, specifically in introns 1 and 2. Cap-
illary sequencing of the PCR products generated yielded
chromatograms that were input into an automated SNP
calling pipeline, which was supplemented with manual
calls from examination of individual sequence traces. A
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total of 72 SNPs, including forty-nine novel variants were
identified.
Genotyping was performed on the Sequenom® MAS-
Sarray® iPLEX® platform. A total of three multiplex geno-
typing reactions were designed, assaying a total of 68
SNPs. The SNPs input to the design software included
those discovered during resequencing (N = 72), as well
as nonsynonymous variants from the literature (N =
25), and several hundred variants within 1 Mb of G6PD
extracted from dbSNP and Ensembl databases. Inclusion
in the multiplex reactions was priority-weighted accord-
ing to predicted functional consequence and estimated
minor allele frequency criteria. Template DNA used for
genotyping was genomic DNA amplified by primer exten-
sion pre-amplification [12]. Genotype calls were manually
curated by examining cluster plots to identify ambigu-
ous genotypes. Ancestral and derived alleles were inferred
according to the Ensembl EPO pipeline.
Data curation and analysis
Enzyme activity data was filtered to keep only individuals
with positive absorbance readings at both 340 and 540 nm,
and checked for batch effects and extreme outliers. Geno-
type data was filtered using custom Perl and R scripts,
along with PLINK [13] and snpMatrix [14]. Individuals
exhibiting greater than 10% missing data or ambigu-
ous gender (based on chromosome X genotypes) were
excluded. SNPs were removed if they showed greater than
5% missing data, minor allele frequency < 1%, or extreme
deviation from Hardy-Weinberg equilibrium (P < 10−4,
Additional file 1). In total, 1828 of 2100 individuals and
30 out of 70 SNPs met these inclusion criteria (Additional
file 2).
Statistical analyses were conducted in R [15]. Sin-
gle marker tests of association for each derived allele
were conducted via multiple linear regression. Covari-
ates included sex, and in the controlled tests, c.202G>A
genotype. Three different modes of inheritance are
considered– in the additive model, male genotypes were
coded 0 or 2, and females were 0, 1, or 2; in the dom-
inant and recessive models, males were coded 0/1, and
females were coded 0/1/1, or 0/0/1, respectively. Haplo-
types were inferred using fastPHASE [16] under default
settings with known male haplotypes used as a reference
input to reduce search space and minimize phasing error
rate in females (Additional file 3). All haplotypes with fre-
quency > 1% (26 full-length, 13 partial) were tested for
association; individuals were coded 0 or 1 based on
absence/presence of the test haplotype, with females rep-
resented by one haplotype selected at random. Odds
ratios (OR) for qualitative tests were calculated via logis-
tic regression. Effect sizes (ES) are presented here with
95% confidence interval in brackets. Allele sharing dis-
tance was calculated using a Euclidean distance metric
for each individual from both H+ and H- haplotypes. An
individual is categorized as either H+ or H- if their dis-
tance metric falls into the lowest quintile of the respective
empirical distribution. In linear modeling of the additive
effect of allele sharing distance on enzyme activity, this
categorization is coded as -1 (H-), 0 (neither), or +1 (H+).
Results
Variants studied
The variants studied here were ascertained using a combi-
nation of sources, including our own resequencing efforts,
published accounts in the literature, and online varia-
tion databases. Resequencing was carried out as part of
an ongoing laboratory effort to catalogue global genetic
variation at the G6PD locus (manuscript in preparation).
A total of 15 kb at the G6PD locus was sequenced in
a worldwide panel comprised of 288 African and Asian
individuals, including 48 from Kenya. This work iden-
tified a total of 72 SNPs, including 49 novel variants.
Published accounts in the literature yielded an additional
25 nonsporadic, nonsynonymous variants associated with
G6PD deficiency in Africa and Asia, including 5 that have
been identified in sub-Saharan Africa [10]: the c.202G>A,
c.376A>G, c.542A>T, c.680G>T, and c.968T>C polymor-
phisms (number refers to cDNA coordinate). Finally, sev-
eral hundred polymorphisms (mostly noncoding SNPs)
within 1 Mb of G6PD were also identified in dbSNP and
Ensembl to supplement our list.
This list of several hundred SNPs was then priority-
weighted according to predicted functional consequence
(e.g. nonsynonymous, splice site, etc.), estimated allele fre-
quency, and proximity to G6PD in order to decide which
would be prioritized for inclusion in genotyping assays. A
total of 68, including all five nonsynonymous African vari-
ants, were typed in the current study using the Sequenom®
MASSarray® iPLEX® platform. Of the SNPs typed, 30
met final study inclusion criteria, which included hav-
ing derived allele frequency (DAF) greater than 0.01 and
less than 5% missing data. It should be noted that most
excluded SNPs failed based on DAF criteria, as many
were private to west Africa or Asia. This included the
c.542A>T, c.680G>T, and c.968T>C variants, which were
monomorphic (DAF = 0%) in Kenya. The only two non-
synonymous variants at the locus that were found to be
polymorphic in Kenya were c.202G>A and c.376A>G,
exhibiting DAF of 17% and 40%, respectively. All SNPs
included in the association study are shown in Additional
file 2.
The c.202G>A polymorphism is themajor determinant of
G6PD activity in Kenya
An initial association scan was performed across thirty
SNPs in 1828 individuals with only gender included
as a covariate. These tests yielded several significant
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associations (Figure 1, Additional file 4), with the max-
imum effect size (ES) and lowest P value recorded at
c.202G>A (ES = -0.22 [-0.23 - -0.21], P = 1.5 × 10−200,
additive model), a nonsynonymous coding SNP
(rs1050828; Val68Met) known to be associated with
G6PD enzyme deficiency in many parts of sub-Saharan
Africa. The effect size for the 202A allele corresponds
to a roughly 40% reduction in enzyme activity for het-
erozygotes, and 80% for hemizygotes and homozygotes,
consistent with previous estimates [17-19]. Since link-
age disequilibrium with c.202G>A was highly correlated
with signal strength at all other sites, we repeated the
association testing including c.202G>A genotype as a
covariate. In these controlled tests, we found strong
evidence of a causal role for 202A, as all other asso-
ciation signals drop off by many orders of magnitude
(Figure 2, Additional file 5), though twelve SNPs still
retained significance at P < 10−3, suggesting a role
independent of c.202G>A, with allelic ES estimates for
each SNP corresponding to 3–4% changes in enzyme
activity.
Modifiers of G6PD activity that are independent of
c.202G>A
As these twelve SNPs exhibited similar P values and effect
size magnitudes (Figure 2, Additional file 5), and were
Figure 1 Fine mapping association study of G6PD activity. a, P-values and b, estimated allelic effect sizes from unbiased association tests
(covariate: gender), with different colors indicating strength of linkage disequilibrium with c.202G>A (purple square). Gene graphic shows exons
(blue) and introns (yellow) for genes annotated at UCSC Genome Browser (hg19); IKBKG=inhibitor of nuclear factor kappa-B kinase subunit gamma.
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Figure 2 Association testing for effects independent of c.202G>A. a, -Log10 P-values and b, estimated allelic effect sizes from ‘controlled’
association tests (covariates: gender, c.202G>Agenotype). The twelve polymorphisms exhibiting significant effects at P < 0.001 are colored
according to whether they exhibit positive ES (green) or negative ES (red). Gene graphic shows exons (blue) and introns (yellow) for genes
annotated at UCSC Genome Browser (hg19); IKBKG=inhibitor of nuclear factor kappa-B kinase subunit gamma.
all common variants (DAF > 0.25) at a locus exhibit-
ing a strong pattern of linkage disequilibrium (Additional
file 6), we considered the parsimonious hypothesis that
they were all related signals. Upon examination of all hap-
lotypes across these twelve sites, it was found that the
two most frequent haplotypes (H+ = 19%; H- = 22%)
were: (a) exactly opposite in allele identity (Figure 3c),
with H+ possessing exactly three derived alleles at sites
with positive ES and H- possessing exactly nine derived
alleles at the sites with negative ES (Figure 2b), and (b) sig-
nificantly different in mean enzyme activity in c.202G>A
wild-type (i.e. 202GG or 202G) individuals (H+: 0.57 vs.
H-: 0.47; P = 9.1 × 10−5, t-test, Figure 3c). In associa-
tion testing of all full-length and twelve-site haplotypes,
it was observed that the haplotypes most suggestive of
association at P < 0.025 similarly exhibited differential
ES direction and resembled either H+ or H- in sequence
identity (Figure 3a and b, Additional file 7). Additionally,
the extent of allele sharing with either the H+ or H- hap-
lotype was correlated with enzyme activity independent
of c.202G>A (P = 2.3 × 10−6, additive linear model,
Additional file 8). Lastly, it was noted that SNPs tagging
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Figure 3 Haplotype-based association testing for effects independent of c.202G>A. Results of association testing of a, full-length and b,
partial/twelve-site haplotypes are shown for all haplotype tests suggestive of association (P < 0.025, covariates: gender, c.202G>A genotype), with
haplotypes defined by patterns of ancestral (blue) and derived (yellow) alleles. SNP labels for the twelve sites that comprise the partial haplotypes
are colored according to whether they exhibited positive ES [green] or negative ES (red) in single SNP controlled tests (Figure 2). c, G6PD activity
distribution in c.202G>Awild-type homozygotes (202G or 202GG) as stratified by carriage of H+, H-, or neither haplotype. Pairwise t-test results are
shown via asterisk (*: P < 0.05 and ***: P = 9.1× 10−5). In box-and-whisker plot, center of box represents median, edges of box represent upper and
lower quartile bounds, and whiskers represent either minimum and maximum values or 1.5 times the interquartile range, whichever is less extreme.
the H+ (rs2230037) and H- (c.376A>G) haplotypes,
in concert with c.202G>A, were sufficient to describe
a minimal adequate genetic model of G6PD activity
that could explain 41% of variance in enzyme activity
(Table 1).
While the association of c.376A>G with a modest
reduction in enzyme activity (approximately 10–20% in
male hemizygotes) has been reported previously [20,21],
and this has been generally thought to be the result of
changes to protein structure leading to enzyme instabil-
ity, it should be emphasized that neither the controlled
association scan nor subsequent haplotype testing was
suggestive of a uniquely causal role for c.376A>G. Indeed,
what our work suggests instead is the possibility that this
nonsynonymous variant is merely a marker, as it is only
one of nine SNPs tagging the H- haplotype and one of
twelve overall that exhibits modest effects independent of
c.202G>A.
Both c.202G>A and c.376A>G contribute to risk of G6PD
deficiency state
We also examined qualitative G6PD activity status, using
the intermodal trough of the bimodal activity distribu-
tion in males as an ad hoc cutoff to distinguish normal
from deficient (Figure 4A, Additional file 9). Overall, using
the clearer distribution profile in males, we estimate that
Table 1 Minimal adequate geneticmodel of G6PD activity
SNP Allelic ES (95% CI) % change
c.202 -0.198 (-0.213 - -0.183) -37.9
rs2230037 (H+) +0.022 (+0.011 - +0.034) 4.3
c.376 (H-) -0.017 (-0.030 - -0.005) -3.3
A linear model containing both c.202G>A as well as SNPs tagging the H+
(rs2230037) and H- (c.376A>G) haplotypes explained significantly more
variance than a model containing c.202G>A alone (P < 0.001), and could
not be improved via the inclusion of additional SNPs.
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Figure 4 Genetic determinants of G6PD deficiency status. a, G6PD activity distribution stratified by genotype at c.202G>A.b, G6PD activity in
202AG heterozygotes stratified by genotype at c.376A>G (NB: the 202A derived allele always exists on a 376G derived allele background), with
contingency table (inset) for qualitative test of association at c.376A>G in 202AG heterozygotes. Also shown in both plots is the reference line (blue)
dividing normal vs. deficient for qualitative tests of G6PD deficiency. In box-and-whisker plots, center of box represents median, edges of box
represent upper and lower quartile bounds, and whiskers represent either minimum and maximum values or 1.5 times the interquartile range,
whichever is less extreme.
the prevalence of G6PD deficiency in our cohort is 18%,
and that 202A accounts for 85% of this figure, which
suggests that there may be rare functional variants we
were underpowered to discover, consistent with observa-
tions elsewhere in east Africa [19]. A total of 162 males
and 97 females could be categorized as deficient, includ-
ing 93% of both 202A hemizygote males and 202AA
homozygote females, but notably also 20% of 202AG
heterozygotes.
While it is known that the distribution of enzyme activ-
ity in 202AG female heterozygotes is broad, with some
individuals exhibiting an effectively deficient biochemi-
cal phenotype, little is known about the genetic factors
that might contribute to this risk. We tested the possibil-
ity that our H- tag SNP, c.376A>G, might reduce enzyme
activity sufficiently to augment risk of phenotypic G6PD
deficiency state in such individuals. The 202A allele is
known to obligately lie on a 376G background in African
populations to form the ‘A-’ haplotype [17,22,23], and
thus 202AG individuals can be either 376GA or 376GG.
We found that among 202AG heterozygotes, those that
were 376GG exhibited not only reduced enzyme activity
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as compared to 376GA (ES = -0.06 [-0.10 - -0.03], P =
0.0009, Figure 4b), a trend consistent with that observed
earlier in 202 wild-type individuals, but were also notably
at increased risk for deficiency state (OR = 2.11 [1.12 -
3.84], P = 0.014). This latter finding has not been pre-
viously reported, and represents the first demonstration
of a genetic modifier that influences risk to deficiency
state in individuals heterozygous for the A- form of G6PD
deficiency.
Discussion
Thework presented here represents the first fine-mapping
association study of enzyme activity at the G6PD locus,
and provides new insights into the genetic basis for
quantitative and qualitative variation in this clinically-
important molecular phenotype. We found that the
largest proportion of variance in G6PD activity could be
explained by a single polymorphism, c.202G>A, a coding
variant thought to be a target of recent positive selec-
tion [24,25], but one that has yielded conflicting results
in previous association studies of severe malaria. In addi-
tion, we found that certain common variants at the locus
modulate G6PD activity independent of c.202G>A, and
identify among these a role for c.376A>G as a genetic
modifier which augments by two-fold the risk of G6PD
deficiency state in 202AG heterozygote females. Taken
together, these results suggest that future clinical asso-
ciation studies in Africa should consider the effects of
both of these variants in order to arrive at a more accu-
rate genetic definition of phenotypic G6PD deficiency
state.
Our study is the first to systematically consider the
possibility that other SNPs, even those found several
hundred kilobases away from G6PD, might be associ-
ated with G6PD deficiency, and that c.202G>Amight only
be indirectly associated with deficiency, a finding which
could explain discrepancies in previous association stud-
ies. Although the number of SNPs surveyed here is rela-
tively small and does not include rare variants, we did not
observe any SNPs more strongly associated with G6PD
deficiency in Kenya than the c.202G>A variant, strongly
suggestive of a causal role. Additionally, while all known
functional variants in sub-Saharan Africa were genotyped
as part of our study, only c.202G>A was found to be poly-
morphic in Kenya (DAF = 17%). This allelic homogeneity
contrasts with the situation in some areas of west Africa
[4], and suggests that given a similar allele frequency
and biochemical penetrance, clinical association studies
of malaria in each region should be equivalently powered
if indeed the G6PD deficiency trait is directly respon-
sible for protection. The strongest evidence implicating
G6PD deficiency in malaria protection would ideally be
consistent with an additive genetic model, with hemizy-
gous males and homozygous females exhibiting similar
clinical phenotypes, and heterozygous females displaying
intermediate phenotypes.
Our work also demonstrates the power of a haplotype-
based approach in resolving multiple correlated asso-
ciation signals in a region. Though we found two
haplotype motifs that were common and of significant
effect independent of c.202G>A, we were unable to fur-
ther localize the signal, even when examining all possi-
ble two- and three-locus haplotypes (data not shown),
suggesting that these haplotypes are merely markers for
the true causal variants. Interestingly, among the twelve
variants of significant effect independent of c.202G>A
were c.376A>G, a nonsynonymous coding variant, as
well as rs915942 and rs111827785, predicted 5’ UTR
splice-site variants within RPL10 (a large-subunit ribo-
somal gene) and G6PD, respectively. While we can only
speculate as to the precise nature of the structure-
function relationship mediating these effects, the biology
of the locus makes for interesting possibilities for interac-
tion between c.202G>A and the H+/H- variants, includ-
ing the possibility of cell-cell interactions synergistically
impacting enzyme activity distribution in 202AG mosaic
females.
At one level, the work presented here reveals how
common, standing genetic variation superimposed on a
Mendelian trait can significantly impact expression of
that trait. More important, however, is how this find-
ing might translate into a better understanding of how
G6PD deficiency is linked to key clinical phenomena.
Specifically, it will be worth considering whether two
site genetic testing is more predictive of clinical out-
come than single SNP testing in women heterozygous
for the common A- form of G6PD deficiency in Africa.
For example, in considering a public health interven-
tion such as mass primaquine administration as part of
a malaria elimination campaign, two-site testing might
help to identify the subset of A- heterozygotes more likely
to be susceptible to acute hemolytic anemia. Lastly, at
a more general level, our work highlights the impor-
tance of measuring intermediate molecular phenotypes
that can bridge the gulf between variance at the genetic
level and variance in clinical phenotypes. This is espe-
cially important for association studies of G6PD defi-
ciency given its considerable allelic heterogeneity, varying
biochemical penetrance, and long history of inconsistent
findings.
Conclusions
We have surveyed genetic variation at the G6PD locus in
Kenya via resequencing, and conducted a fine-mapping
association study of erythrocyte G6PD activity. We find
that while the c.202G>A polymorphism accounts for most
of the variance in enzyme activity seen in this population,
several other common polymorphisms are also relevant,
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specifically noting that c.376A>G acts as a genetic modi-
fier which increases by two-fold the risk of deficiency state
in 202AG heterozygotes. Our results suggest that multi-
ple alleles at the G6PD locus play a role in determining
G6PD deficiency state and therefore merit consideration
in genetic association studies of clinical phenotypes such
as severe malaria or drug sensitivity.
Additional files
Additional file 1: Quality control plots. Shown here are plots that
examine: (a) whether any individuals with low call rate and high
heterozygosity (left), or (b) whether any SNPs with low call rate and
extreme deviation from HWE (right) could be found, features indicative of
low confidence samples and SNPs, respectively.
Additional file 2: SNP summary table. Shown here for each SNP assayed
is: the genomic position (hg19/GRCh37), observed alleles (on the
[+]-strand, according to UCSC Genome Browser), ancestral allele
(according to the Ensembl EPO pipeline), G6PD exon-intron position
(according to UCSC genome annotation coordinates), and derived allele
frequency stratified by sex. Key: E=exon, I=intron, US=upstream,
DS=downstream. NB: c.202 and c.376 are referred to by their coding strand
(-) allele designations throughout for clarity.
Additional file 3: Haplotype distribution inmales vs. females. The
frequency of each haplotype is plotted in decreasing order, stratified by sex
(top, males=dark bars, females=light bars). No significant differences
between male and female haplotype frequencies were found, attesting to
highly accurate haplotype phasing (bottom).
Additional file 4: Initial association test results. Shown here for each
SNP surveyed is: genomic position (hg19/GRCh37), DAF stratified by sex, P
values and effect sizes (with 95% CI) for initial, uncontrolled association
tests under three different genetic models.
Additional file 5: Association test results for effects independent of
c.202G>A. Shown here for each SNP surveyed is: genomic position
(hg19/GRCh37), DAF stratified by sex, P values and effect sizes (with 95%
CI) for c.202G>A-controlled association tests under three different genetic
models.
Additional file 6: Linkage disequilibrium (LD) across region. Pairwise
LD matrix is shown in colorimetric form, using the D’ and LOD metrics.
Colors indicate: D’ = 1 and LOD ≥ 2 (red), D’ = 1 and LOD ≤ 2 (blue), D’ < 1
and LOD ≥ 2 (pink), D’ < 1 and LOD ≤ 2 (white).
Additional file 7: Association test results of full-length and partial
haplotypes for effects independent of c.202G>A. Shown here for each
haplotype surveyed is: allele identity across all sites (0=ancestral,
1=derived, _=either), population frequency, P values and effect sizes (with
95% CI) for c.202G>A-controlled association tests.
Additional file 8: Allele sharing with H+ or H- explains variance
independent of c.202G>A. G6PD activity as stratified by sex and
haplogroup, where the latter is defined by categorizing each individual
according to extensive allele sharing with either the H+, H-, or neither
haplotype (see Methods). In box-and-whisker plots, center of box
represents median, edges of box represent upper and lower quartile
bounds, and whiskers represent either minimum and maximum values or
1.5 times the interquartile range, whichever is less extreme. The P-value
displayed in the figure represents the statistical significance of allele
sharing under a linear model which incorporates c.202G>A genotype and
gender as covariates (NB: sex-stratified testing reveals Pmale = 8.8 × 10−5
and Pfemale = 6.2 × 10−4).
Additional file 9: Defining qualitative G6PD deficiency. The
intermodal minimum in the G6PD activity distribution in males was
determined using kernel density estimation of the probability density
function (red) and provided our ad hoc cutoff (blue) for distinguishing
normal vs. deficient. A histogram of the G6PD activity distribution in males
is superimposed for clarity.
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